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Abstract
Improving the antitumor potency of current oncolytic adenoviruses represents one of the major challenges in
development of these viruses for clinical use. We have generated an oncolytic adenovirus carrying the safety-
enhancing E1AD24 deletion, the potency-enhancing T1 mutation, and the infectivity-enhancing fiber RGD
modification. The results of in vitro cytotoxicity assays on 15 human cancer cell lines derived from different
tumor types demonstrated that ORCA-010 is more potent than Ad5-D24RGD or ONYX-015. As ORCA-010
will initially be developed for the treatment of prostate cancer, selectivity experiments were performed using
primary human prostate cells. ORCA-010 killed cancer cells more effectively than these primary human cells.
In both primary prostate fibroblasts and epithelial cells, ORCA-010 was as safe as Ad5-D24RGD. Evaluation of
ORCA-010 in in vivo xenograft tumor models in nude mice showed that ORCA-010 significantly inhibited
growth of prostate, lung, and ovarian tumors and conferred prolonged survival of tumor-bearing animals.
Furthermore, we observed a substantial increase in infectious viral particles in tumors injected with ORCA-010.
The number of infectious viral particles increased after treatment and infectious particles remained present up to
at least 4 weeks posttreatment. Intratumoral virus replication was associated with substantial necrosis and
fibrosis. In conclusion, ORCA-010 is more potent than earlier generation oncolytic adenoviruses, without
demonstrating increased toxicity. ORCA-010 exerted strong in vivo antitumor activity and is therefore a suitable
candidate for clinical evaluation.
Introduction
Despite extensive research and development towardnew diagnostics and therapeutics, cancer still is one of
the leading causes of death worldwide. The complexity of the
disease and frequent inherent or acquired resistance against
treatment form great challenges to achieve complete cures.
To increase the cure rate for cancer patients, treatment op-
tions based on new mechanisms of action are urgently nee-
ded. Oncolytic viruses have attracted considerable attention
as a promising approach for the treatment of cancer. Owing to
their ability to replicate within the cancer cell, oncolytic
viruses have unique pharmacokinetic properties that differ-
entiate them from conventional small molecule or biological
therapeutics. More than 10 different virus groups are cur-
rently being explored for the development of virotherapies
(Russel et al., 2012). Of these, adenovirus is most widely used.
Oncolytic adenoviruses are engineered to specifically
replicate in and kill malignant cells. To ensure that the virus
selectively replicates in cancer cells, different strategies
have been used (Alemany, 2007). Two paradigm examples
of oncolytic adenoviruses are ONYX-015 (Bischoff et al.,
1996) and A5-D24 (Fueyo et al., 2000). To ensure cancer
cell–selective replication, ONYX-015 carries a deletion of
the E1B55K gene and Ad5-D24 carries a small deletion in
the E1A gene. Previous studies have shown that viruses with
the D24 mutation have superior oncolytic potency compared
with ONYX-015 (Heise et al., 2000; Lockley et al., 2006).
The D24 mutation is a 24-nucleotide deletion in the CR2
domain of E1A, which results in abolishment of the binding
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of E1A to the host cell retinoblastoma tumor suppressor
protein (pRb). During wild-type adenovirus replication in
normal cells, the binding of E1A to pRb is required to en-
sure release of the cell cycle transcription factor E2F-1.
Release of E2F-1 forces the cell into cell cycle (S phase) and
promotes replication of the adenovirus by driving expres-
sion of the viral E2 gene region. Conversely, loss of this
E1A function renders the adenovirus replication incompe-
tent in normal cells with a functional pRb pathway. In
contrast, viruses with the D24 mutation replicate efficiently
in tumor cells where sequestration of pRb by E1A is not
necessary, because in most cancers the pRb/p16 pathway is
defective (Fueyo et al., 2000; Heise et al., 2000).
Although evidence of biological activity was obtained in
clinical trials, overall the observed efficacy of oncolytic
adenoviruses as single agents has been modest. Hence, im-
provement of the potency of oncolytic adenoviruses is re-
quired to achieve the desired clinical efficacy. To accomplish
this, several strategies have been taken. A first approach is the
insertion of transgenes, leading to augmented therapeutic ef-
ficacy. Various genes have been incorporated into the ade-
novirus backbone for this purpose, such as genes encoding
tumor suppressor p53 (Van Beusechem et al., 2002), various
prodrug-converting enzymes (Wildner et al., 1999), and im-
mune modulators (Lei et al., 2009). A second approach has
been the isolation of mutant adenovirus variants with aug-
mented replication in cancer cells through genetic bioselec-
tion. Using this approach, AdT1 virus expressing a mutant
E3/19K protein lacking the endoplasmic reticulum retention
domain was isolated (Gros et al., 2008). The mutant E3/
19K-T1 protein relocates to the plasma membrane and in-
duces membrane permeabilization causing enhanced release
of progeny virus from infected cancer cells. A third ap-
proach has been to promote oncolytic adenovirus entry into
cancer cells by changing or expanding its tropism. A par-
ticularly effective modification has been the insertion of an
RGD motif in the adenovirus fiber protein (Suzuki et al.,
2001). The RGD motif consists of a 9-amino acid peptide
(CDCRGDCFC) that binds to integrins (particularly avb3 or
avb5). Insertion of this RGD motif in the HI loop of the
fiber protein of adenovirus results in enhanced infectivity in
a number of different cancer cell lines (Dimitriev et al.,
1998; Suzuki et al., 2001).
With the aim to generate an oncolytic adenovirus with
further enhanced anticancer potency, we here combine the
efficacy-enhancing E3/19K-T1 and fiber RGD elements
with the D24 mutation conferring cancer cell selectivity in
an Ad5 backbone. We evaluate the lytic replication of the
new virus ORCA-010 on malignant and nonmalignant
cells in vitro and in three different xenograft tumor models
in vivo. We demonstrate that ORCA-010 has superior on-
colytic potency compared with earlier generation oncolytic
adenoviruses. The data presented here show that ORCA-010




FaDu, UM-SCC-11B, UM-SCC-14C, UM-SCC-22A, and
VU1131 head and neck squamous cell carcinoma cell lines,
SK-Mel-28 melanoma cells, A549 lung adenocarcinoma
cells, NIH OVCAR-3 ovarian cancer cells, MDA-MB-231
breast cancer cells, Hep3B hepatocellular carcinoma cells,
U2OS osteosarcoma cells, HCT 116 colorectal carcinoma
cells, and 911 AdE1-complementing human embryonic re-
tinoblasts (Fallaux et al., 1996) were cultured in DMEM
(Lonza). The prostate cancer cell lines PC-3, LNCaP, and
DU-145 were cultured in RPMI 1640 (Lonza). All media
were supplemented with 10% FBS (Greiner) and 0.5% pen/
strep (Lonza). Cells were split twice a week and incubated at
37C with 5% CO2. Primary human prostate epithelial cells
and primary human prostate fibroblasts were purchased from
Sciencell and cultured in a cell-specific medium supple-
mented with 10% FBS and 0.5% pen/strep (Sciencell). Cells
were split at 90% confluency and were cultured at 37C
with 5% CO2.
Viruses
Wild-type adenovirus serotype 5 (Ad5) was provided
by Prof. Rob Hoeben (Leiden University Medical Center,
The Netherlands). The oncolytic adenoviruses ONYX-015,
Ad5-D24, and Ad5-D24RGD have been described before.
ONYX-015 carries an E1B-55K deletion mutation (Bischoff
et al., 1996). Ad5-D24 (Fueyo et al., 2000) contains a 24 bp
deletion at position 923–946 of the E1A gene (E1AD24) in
Ad5. Ad5-D24RGD carries the same E1A modification and
a cyclic RGD insertion in the HI loop of the fiber (Suzuki
et al., 2001). To generate new oncolytic adenoviruses Ad5-
D24T1 and Ad5-D24RGD-T1 (ORCA-010), homologous
recombination (HR) technology in the yeast strain YPH-857
was used with the LiAc high-efficiency transformation
protocol (Gietz et al., 2007).
The oncolytic adenovirus plasmid pAd5-D24T1, with the
E1AD24 mutation and the potency-enhancing E3/19K-T1
mutation, was generated by HR between a 14 kb AleI-AleI
cut fragment from plasmid pAdE3/19K-445A (Gros et al.,
2008) containing the E3/19K-T1 mutation and pAd5-
D24RGD (Suzuki et al., 2001) from which we excised the
27.5 kb PacI-SrfI fragment containing the RGD motif. To
generate pAd5-D24RGD-T1 comprising the E1AD24 dele-
tion, E3/19K-T1 mutation, and the RGD motif insertion
in the HI loop of the fiber, HR was done with a 26 kb PmeI-
PacI fragment containing the RGD motif of pAd415-
D24RGD-T1 and pAd5-D24T1, from which we excised the
29.5 kb NdeI-NdeI fragment carrying the wild-type fiber
gene. Viruses were generated by lipofectamine 2000 trans-
fection (Invitrogen) of PacI linearized plasmids and prop-
agation in A549 cells.
For generation of concentrated virus stocks, virus was
purified using the Vivapure adenopack 100 kit (Sartorius
Stedim Biotech S.A.) and stored in a 10 mM Tris (pH 7),
25 mM NaCl buffer containing 2.5% w/v glycerol. E1AD24,
T1, and RGD modifications were confirmed in all plasmids
and viruses by sequence analysis. Restriction analysis was
performed on plasmids and viruses to verify that Ad5-
D24T1 and ORCA-010 are derived from the adenovirus
reference material (Sugarman et al., 2003).
Infectious virus titers were determined with an antihexon
immunocytochemistry (ICC) assay using the Adeno-X Rapid
Titer Kit (Clontech) according to the manufacturer’s protocol.
The following adaptations were made to this protocol: instead
of HEK293 cells, 911 cells were used, and volumes of
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reagents were adjusted for use in 96-well plate format. De-
termination of virus particle titers in purified preparations was
done spectrophotometrically using the GeneQuant spectro-
photometer (Amersham Pharmacia) (Maizel et al., 1968),
using a conversion factor of 1.1 · 1012 viral particles per
absorbance unit at 260 nm.
In vitro cytotoxicity assay
Cytotoxicity assays on human cancer cell lines were
performed by infecting 5,000 cells seeded per well in 96-
well plates with 2-fold serial virus dilutions ranging from
8 · 102 to 3.8 · 10 - 4 IU/cell for ONYX-015 and 1 · 102 to
4.8 · 10 - 5 IU/cell for all other viruses. Virus replication was
allowed to proceed for 5–9 days on Hep3B, A549, U2OS,
HCT 116, SK-Mel-28, UM-SCC-22A, LNCaP, NP9, and
DU-145 cells and for 10–15 days on UM-SCC-11B, UM-
SCC-14C, PC-3, VU1131, MDA-MB-231, and FaDu cells.
After incubation, plates were washed with PBS and stained
using the BCA assay kit (Pierce). Virus was inactivated by
addition of SDS (final concentration 1%). The absorbance
was measured at 595 nm using the Benchmark microplate
reader (BioRad). For cytotoxicity assays on primary cells,
the cells were first grown to quiescence. To this end, 20,000
cells per well were seeded in a 96-well plate and cultured for
7 days with medium change at 4 days postplating. At 6 days
postplating, the number of Ki-67-positive cells was deter-
mined by ICC staining to verify quiescence. Cells were
fixed with 10% formalin, stained with anti-Ki-67 antibody
M7240 (Abcam) and secondary HRP-conjugated rabbit an-
timouse antibody Ab6728 (Abcam), and developed with
3,3¢-diaminobenzidine. At 7 days postplating, cells were
infected with serial dilutions of virus as described above.
Cultures were maintained for a maximum of 10 days, which
is the maximum feasible time to culture these cells without
change of medium and no significant loss of viability. Plates
were washed with PBS and viability was determined with
the CellTiter-Blue assay (Promega) and a Tecan Infinite
F200 microplate reader at 540 nm excitation and 590 nm
emission wavelengths.
The virus concentration required to kill 50% of the
cells (EC50) was calculated from the dose–response curves
by standard nonlinear regression using a sigmoidal dose–
response equation (GraphPad Prism). The inverse of the
EC50 (1/EC50) is used as a measure of the cytotoxicity of the
different viruses. Results are expressed as a mean ( + standard
error) of triplicate samples from at least two independent
experiments.
In vivo antitumor efficacy
Balb/c nu/nu mice (Charles River Laboratories) were
housed in a 12 hr light/dark cycle, with ad libitum access to
food and water. All animal procedures were conducted in
accordance with the European Community Council directive
(86/609/EEC) for the care and use of laboratory animals.
Human PC-3 prostate cancer cells (2 · 106) or A549 lung
cancer cells (1 · 107) were resuspended in 50 ll of 50%
DMEM/50% Matrigel solution (Becton Dickinson) and in-
jected subcutaneously into the flank of 5–6-week-old mice
to establish tumor xenografts. The tumor volume was de-
termined 1–3 times a week using a digital caliper. Once
tumors reached a volume of 80–150 mm3, the animals were
randomized over groups of 7–8 mice and injected in-
tratumorally on 3 subsequent days with purified ORCA-010
virus (total dose 1.3 · 107, 1.3 · 108, 1.3 · 109, or 1.3 · 1010
VP; VP:IU ratio of 13:1) or diluent without virus (control).
To establish NIH OVCAR-3 xenografts, 8–9-week-old
Balb/c nu/nu mice were used. Animals underwent whole-
body irradiation with 2 Gy c irradiation before injection of
1 · 107 NIH OVCAR-3 cells into their flank.
Tumor sizes and animal body weights were recorded 1–3
times per week, and tumor volumes were calculated ac-
cording to the formula V (mm3) = (4/3 · p · [width + length]/
4)3. When tumors reached a size of 2,000 mm3, the animals
were sacrificed for ethical reasons. PC-3 and A549 tumors
were dissected and embedded in paraffin for hematoxylin–
eosin staining. Tumor growth was analyzed in GraphPad
Prism and the two-tailed Student’s t-test was used for
comparing the tumor progression in the different treatment
groups. Kaplan–Meier survival curves were generated in
GraphPad Prism based on number of days required to reach
a tumor volume of 2,000 mm3. Statistical analysis was done
with a Log-Rank Mantel Cox test comparing survival of
treated groups with the control group.
Analysis of intratumoral adenovirus replication
Balb/c nu/nu mice bearing pre-established PC-3 xeno-
grafts (121–623 mm3) were injected intratumorally with a
single dose of 4.3 · 109 VP ORCA-010 virus. At 3, 7, 14, 21,
and 28 days posttreatment, animals were sacrificed. The
tumors were fixed in formalin and embedded in paraffin.
Sections of 5 lm were prepared for HE or Masson’s tri-
chrome (Polysciences, Inc.) staining or stained for presence
of adenovirus using an antihexon antibody. Antigen retrieval
was done by heating in Tris/EDTA buffer. Specific mono-
clonal antihexon antibody (Ab8249; Abcam) and a sec-
ondary HRP-labeled rabbit antimouse antibody (Ab6728;
Abcam) were used. The sections were developed with 3,3¢-
diaminobenzidine and counterstained with hematoxylin.
Results and Discussion
Construction of the new oncolytic
adenovirus ORCA-010 (Ad5-D24RGD-T1)
Human adenovirus serotype 5 (Ad5)-derived oncolytic ad-
enovirus ORCA-010 was constructed by introducing the
E1AD24 mutation providing cancer cell-selective replica-
tion (Fueyo et al., 2000), the infectivity-enhancing cyclic-
RGD insertion in the fiber (Dimitriev et al., 1998; Suzuki
et al., 2001), and the E3/19K-T1 mutation promoting cell
lysis and virus progeny spread (Gros et al., 2008) into the
Ad5 genome (Fig. 1). Restriction and sequencing analysis of
pAd5-D24RGD-T1 and DNA isolated from ORCA-010 virus
propagated in A549 cells confirmed that the virus carried the
relevant E1AD24, T1, and RGD modifications in an Ad5
reference material backbone (Sugarman et al., 2003).
ORCA-010 displays enhanced
oncolytic potency in vitro
To evaluate the oncolytic potency of ORCA-010, we
compared the new virus in a set of in vitro cytotoxicity
assays with a panel of earlier generation oncolytic adeno-
viruses. These viruses included ONYX-015 (Bischoff et al.,
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1996) that carries an E1B-55K deletion mutation and has
been thoroughly evaluated in numerous human clinical tri-
als. Furthermore, Ad5-D24, which carries a 24 nt deletion
mutation in the Rb-binding domain of E1A and was shown
to be a more potent cancer cell killer than ONYX-015
(Heise et al., 2000; Lockley et al., 2006), was used. Finally,
to dissect the contribution of the RGD and T1 mutations to
ORCA-010’s oncolytic properties, Ad5-D24RGD (Suzuki
et al., 2001) and Ad5-D24-T1 each carrying one of these
modifications were included. The assays were done on 15
human cancer cell lines from different tissue origins. Cells
were infected with a dilution series of the respective viruses
and incubated to allow for virus replication. As adenovirus
replicates with different efficiency on different cell lines, the
culture duration was adapted accordingly. Dose–response
curves were made (representative example in Fig. 2A), and
the inverse of the virus dose required to reduce cell viability
by 50% (1/EC50) was calculated as a measure for oncolytic
potency. Figure 2B shows the results obtained for each virus
on each cell line. Individual cancer cell lines exhibited
considerable differences in susceptibility to lytic adenovirus
replication. This could be because of differential expression
of the natural Ad5 high-affinity receptor coxsackie adeno-
virus receptor (CAR) on the cells, or on their inherent dif-
ferences in supporting adenovirus DNA replication, late
gene expression, and/or viral release (van Beusechem et al.,
2002; Royds et al., 2006).
On individual cell lines, ORCA-010 was at least as potent
or up to 60-fold more potent as the most effective earlier
generation virus Ad5-D24RGD. Figure 2C shows the average
potency enhancement on the panel of cancer cell lines that
each Ad5-D24-based variant virus exhibited relative to
ONYX-015. As can be seen, Ad5-D24-based viruses were
much more potent than ONYX-015, confirming earlier ob-
servations. On average, introduction of the T1 (Ad5-D24T1)
or RGD (Ad5-D24RGD) mutation into Ad5-D24 enhanced
the potency of the virus approximately 3- and 4-fold, respec-
tively. ORCA-010 that comprises both potency-enhancing
modifications displayed an even greater enhanced potency
than could be expected from the additive effects of the
two modifications. ORCA-010 was on average 33-fold more
potent than Ad5-D24, 10-fold more potent than Ad5-D24T1,
and 7-fold more potent than Ad5-D24RGD. These results
confirm that the T1 mutation and the RGD fiber insertion
increase the oncolytic potency of Ad5-D24-variant viruses
and suggest that when combined they might work syner-
gistically to enhance oncolytic adenovirus potency.
Selectivity of ORCA-010 lytic replication
As ORCA-010 will initially be developed for local
treatment of prostate cancer, the cells most exposed to the
virus upon clinical administration are cells present in the
prostate of the patient. Therefore, the selectivity of the virus
was evaluated by comparing its in vitro cytotoxic potency
on primary human prostate epithelial cells and primary
human prostate fibroblasts versus PC-3 and A549 cancer
cells. To mimic the in vivo quiescent state, primary cells
were cultured until they grew confluent and became quies-
cent. The quiescent state of the primary cells was confirmed
FIG. 1. Construction of ORCA-010 and comparison of genome structures with wild-type Ad5. A schematic representation
of the excised DNA fragments used for homologous recombination to generate Ad5-D24-T1 (A) and Ad5-D24RGD-T1 (B).
Homologous recombination occurred in the indicated areas (HRI and HRII). (C) Differences between the DNA sequences
of ORCA-010 and Ad5: a 24 nt deletion in the E1A gene encoding 8 amino acids of the pRb-binding domain; a single A
insertion at nucleotide position 445 of the E3/19K gene causing a frame shift introducing a premature stop codon resulting
in a protein lacking the ER-retention domain (T1 mutation); and a 21 nt insert in the HI-loop of the fiber gene encoding a
cyclic RGD-4C integrin-binding domain (amino acid sequence given).
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by Ki-67 staining before addition of virus. Quiescent pri-
mary cell cultures contained less than 1% Ki-67-positive
cells. They could be maintained in culture for another 10
days without loss of viability or increase of percentage of
Ki-67-positive cells. However, it cannot be completely ruled
out that some proliferation occurred in the primary cell
cultures, as it is not possible to fully mimic the in vivo
conditions in an in vitro environment. In the in vitro se-
lective cytotoxicity experiments, Ad5 and Ad5-D24RGD
were included for comparison. As can be seen in Fig. 3, Ad5
and both oncolytic adenoviruses replicated much more ef-
ficiently in cancer cells than in quiescent nonmalignant
cells. As expected, the two oncolytic viruses were less toxic
to prostate epithelial cells than Ad5. In contrast, they were
more potent than Ad5 on prostate fibroblasts. This is prob-
ably because of the insertion of the integrin-binding RGD
motif in the fiber protein of ORCA-010 and Ad5-D24RGD
mediating more efficient entry of the virus into these cells
that express very low levels of the natural Ad5 high-affinity
receptor CAR (Hidaka et al., 1999). Importantly, while
ORCA-010 displayed enhanced oncolytic potency compared
with Ad5 and Ad5-D24RGD on PC-3 and A549 cancer
cells, its cytotoxicity on nonmalignant prostate cells was
comparable to that of Ad5-D24RGD. Hence, the T1 muta-
tion in ORCA-010 caused a cancer cell–selective potency
enhancement, increasing the therapeutic window.
FIG. 2. Comparative cytotoxicity evaluation of ORCA-010 and earlier generation oncolytic adenoviruses. The cytotox-
icity of different oncolytic adenoviruses was evaluated in in vitro cytotoxicity assays on 15 different human cancer cell
lines. (A) Exemplary dose–response curves obtained on A549 cells. The EC50 values derived from these curves were used
to calculate oncolytic cytotoxicity (1/EC50). (B) Mean cytotoxicities of each virus on each cancer cell line, derived from at
least two independent experiments. (C) The mean cytotoxicity of each virus on the panel of cancer cell lines was calculated
and is given relative to the potency of ONYX-015, which was set at 1. Bars in (B) and (C) depict means; error bars show
standard errors of the mean.
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ORCA-010 exhibits antitumor activity against
human tumor xenografts in vivo
The in vivo antitumor activity of ORCA-010 was inves-
tigated in nude mice bearing subcutaneous human prostate
cancer (PC-3), lung cancer (A549), or ovarian cancer (NIH
OVCAR-3) xenografts. Established tumors were injected
with ORCA-010. PC-3 and A549 tumors received dosages
of 1.3 · 107 VP, 1.3 · 108 VP, 1.3 · 109 VP, or 1.3 · 1010
VP; NIH OVCAR-3 tumors were treated only at the highest
dose. Treatment with ORCA-010 resulted in significant in-
hibition of tumor growth compared with vehicle-injected
control tumors in all three models (Fig. 4A–C). Although a
clear dose–response was not observed, analysis of tumor
growth and survival showed that in mice xenografted with
prostate tumors, injection of the highest dose of 1.3 · 1010
VP resulted in the most profound antitumor response. In all
models, animals treated intratumorally with ORCA-010 had
an increased survival compared with the control animals
(Fig. 4D–F). In the highest dose group, 80% of the animals
survived until the end of the study with no tumor or a tumor
smaller than 2,000 mm3 (i.e., the tumor size defined as hu-
mane endpoint requiring sacrifice of the animal). In all dose
groups of the PC-3 and A549 models, one or two animals
did not bear a detectable tumor at the end of the study.
FIG. 3. Comparative cytotoxicity evaluation of ORCA-
010 on cancer cells and primary prostate cells. Quiescent
primary human prostate epithelial (HPE) cells and human
prostate fibroblasts (HPF) and A549 and PC-3 cancer cells
were infected with serial dilutions of Ad5, Ad5-D24RGD,
and ORCA-010. Seven days after infection (A549) or 10
days after infection (HPE, HPF, and PC-3), cell viability
was measured and used to calculate cytotoxicity (1/EC50).
Data are means with SE of at least 2 independent triplicate
experiments.
FIG. 4. Antitumor activity of ORCA-010 in subcutaneous human tumor xenografts in vivo. Mice bearing subcutaneous
PC-3 (A, D), A549 (B, E), or NIH OVCAR-3 (C, F) xenografts were injected intratumorally with ORCA-010 at the
indicated dosages or with diluent. (A–C) Mean tumor volumes with standard error of treatment groups are given until the
first animal of the group had to be sacrificed because its tumor size exceeded 2,000 mm3. At this point, that is, day 28 for
PC-3, day 30 for A549, and day 45 for NIH OVCAR-3, significance of growth inhibition was tested. p-Values of each
treatment group compared with the diluent-injected group are given in the panel legends. (D–F) Kaplan–Meier curves
depicting survival with a tumor smaller than 2,000 mm3. p-Values of treatment groups compared with the diluent group are
given. ‘‘X’’ marks indicate animals that had to be sacrificed while bearing a tumor smaller than 2,000 mm3 for ethical
reasons, that is, with an open necrotic wound at the site of the tumor.
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Necropsy and/or histological analysis confirmed that these
animals were indeed tumor-free (not shown).
ORCA-010 replicates in PC-3 tumor xenografts
The in vivo replication and intratumoral spread of ORCA-
010 was investigated in animals bearing subcutaneous PC-3
xenografts. Animals were treated with a single intratumoral
injection of 3.3 · 108 IU of ORCA-010 and were sacrificed
at different time points after injection. Dissected tumors
were used to determine the infectious viral titer by ICC
assay (Fig. 5A) and to visualize viral spread by immuno-
histochemistry (Fig. 5B and Supplementary Fig. S1; Sup-
plementary Data are available online at www.liebertpub
.com/hum). As can be seen in Fig. 5A, infectious adenovirus
could be recovered from injected tumors at all tested time
points. The total virus load in tumors was always higher
than the input dose. At days 7 and 14, the virus load was 200
times higher than the injected dose. It could thus be con-
cluded that ORCA-010 replicated in PC-3 tumors in vivo
and that viable virus was retained in PC-3 tumors until at
least 28 days posttreatment. Immunohistochemical analysis
on tumor tissue sections confirmed the presence of hexon-
positive cells in tumors at days 3, 7, and 14. Figure 5B
shows a tumor analyzed 7 days after injection. Virus-in-
jected tumors contained large necrotic areas (indicated in
the HE-stained section) with fibrosis (Masson’s trichrome
staining). Hexon-positive cells were found primarily in the
viable tumor tissue surrounding necrotic areas. This sug-
gested that the necrosis was caused by the replicating virus.
Therapeutic utility and perspectives
for clinical development of ORCA-010
As shown here, the new oncolytic virus ORCA-010,
containing a combination of the efficacy-enhancing E3/19K-
T1 and fiber RGD elements in the Ad5-D24 backbone, ex-
hibited superior oncolytic potency compared with Ad5-D24,
Ad5-D24RGD, and the first-generation oncolytic adenovi-
rus ONYX-015. The T1 mutation and the RGD motif in-
dependently enhanced the oncolytic potency and when
combined displayed a supra-additive effect. Further studies
showed that ORCA-010 kills cancer cells more effectively
than primary nonmalignant cells. Despite the enhanced po-
tency, ORCA-010 was as selective as Ad5-D24RGD, which
was shown to be safe for use in humans up to 3 · 1012
FIG. 5. ORCA-010 repli-
cation upon intratumoral
injection in PC-3 prostate
tumor xenografts in vivo.
Tumors were injected with
4.3 · 109 VP (3.3 · 108 IU)
ORCA-010 and collected at
3, 7, 14, and 28 days post-
injection. (A) Tumors were
homogenized and total infec-
tious virus content (IU) was
determined by immunocyto-
chemistry titration assay. (B)
(Immuno)histochemical anal-
ysis of a tumor collected at 7
days after ORCA-010 injec-




blue), or with an antibody
against the adenovirus hexon
protein counterstained with
hematoxylin (hexon IHC), as
indicated. Pictures were taken
at 2.5- and 40-fold magnifi-
cation, as indicated. The dot-
ted line in the HE staining
indicates the border between
viable tumor tissue and ne-
crotic tissue. The rectangle
in the hexon IHC at 2.5-fold
magnification indicates an
approximation of the mag-
nified area shown in the
40-fold magnification. Hexon
protein-positive cells are stained
brown.
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viral particles (Kimball et al., 2010; Pesonen et al., 2012;
Clemens Dirven, personal communication). Moreover, in-
tratumoral injection of ORCA-010 in human prostate,
ovarian, and lung cancer tumors xenografted in immune-
deficient mice resulted in significant inhibition of tumor
growth and prolonged survival. Taken together, these data
support progression of ORCA-010 toward further preclinical
safety testing in anticipation of a first clinical trial. In this
respect, recent data of an ongoing clinical trial of Ad5-
D24RGD in patients with glioblastoma multiforme are very
encouraging. It was reported that half of the patients who
received a single intratumoral injection of Ad5-D24RGD
(DNX-2401) as first-line therapy showed stabilization or
partial or complete regression of their disease (Pol et al.,
2013). Here, we have shown that ORCA-010 has superior
oncolytic potency compared with Ad5-D24RGD in a wide
variety of cancer types. Altogether, this warrants further
clinical development of ORCA-010, in particular for cancers
with a high medical need for local tumor control. Therefore,
ORCA-010 will first be developed for treatment of patients
with locally recurrent prostate cancer.
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